A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma
Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.
Case: A 74-Year-Old Man with Diffuse Large B-Cell Lymphoma
Initial Presentation
- A 74-year-old man presented with fever, 14-lb unintentional weight loss and occasional chest pain
- PMH: DM, medically controlled
- PE: tired-appearing man; palpable bilateral cervical lymphadenopathy
Clinical Work-up
- Labs: LDH 2 times above normal; Hb 10.8 g/dL; bilirubin 2.3 mg/dL; creatinine 1.7 mg/fl; all others WNL
- Hepatitis B, C and HIV negative
- Lymph node biopsy; CD 20+ confirmed DLBCL; IHC panel: CD 10+, CD 19+
- Imaging:
- Whole body PET/CT scan showed activity the cervical lymph node region, largest node 2.5 cm; evidence of axillary and thoracic subcutaneous tissue involvement
- Ann Arbor stage 4; IPI: high-risk; ECOG PS 1
Treatment
- Treatment initiated with R-CHOP + RT; well-tolerated
- Interim PET scan after 4 cycles; progressive diseases noted
- Due to transplant ineligibility patient was treated with tafasitamab + lenalidomide
Peers Discuss Role of Pola-R-CHP vs R-CHOP in Newly Diagnosed DLBCL
April 19th 2024During a Case-Based Roundtable® event, Haifaa Abdulhaq, MD discussed with participants whether the POLARIX trial influences their choice to use the pola-R-CHP as opposed to R-CHOP regimen for patients with newly diagnosed diffuse large B-cell lymphoma.
Read More
Glofitamab Plus Chemo Improves Survival vs Rituximab in R/R DLBCL
April 16th 2024The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Read More
Comparing Results with Loncastuximab in the Clinic and Real-World Settings in DLBCL
April 1st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the long-term results with loncastuximab in patients with diffuse large B-cell lymphoma and how this drug fared in the real-world setting in the second article of a 2-part series.
Read More
Fitting Loncastuximab Into the Current Landscape of R/R DLBCL
March 21st 2024During a Case-Based Roundtable® event, Emily Ayers, MD, discussed the current landscape for the treatment of patients with diffuse large B-cell lymphoma, the need for better risk stratification data, and what led to the approval of loncastuximab tesirine in the first article of a 2-part series.
Read More
